LIAN

LianBio [LIAN] Stock Forecast

Q: What is LianBio stock symbol ?

LianBio is a US stock, located in Princeton of Nj and trading under the symbol LIAN

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

LIAN Stock Summary

LIAN has more than 2 years of cash runway (25 months)

Top 10 Correlated ETFs

LIAN

Top 10 Correlated Stocks

LIAN

In the News

04:15 29 Sep 2023 LIAN

LianBio to Participate in Upcoming Investor Conferences

SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the following upcoming investor conferences:

12:02 29 Sep 2023 LIAN

LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China

As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.

09:33 29 Sep 2023 LIAN

Penny Stocks To Buy Now? 6 To Watch With Big News Today

Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?

11:24 29 Sep 2023 LIAN

Best Penny Stocks To Buy Now? 4 To Watch As APE Stock Goes Public

Hot penny stocks to watch but are they a buy now or not? Let's look at the catalysts.

11:41 29 Sep 2023 LIAN

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

07:22 29 Sep 2023 LIAN

LianBio Stock (LIAN): Why The Price Surged Today

The stock price of LianBio (NASDAQ: LIAN) increased by 19.67% today. This is why it happened.

06:33 29 Sep 2023 LIAN

Medical Device Maker Highlights China Risk As Chinese U.S. IPOs Resume

Meihua International files updated prospectus highlighting China oversight risk in latest filing for its modest $57 million U.S. IPO.

12:31 29 Sep 2023 LIAN

China-U.S. IPO Pipeline Creaks Back To Life With 2 New Listing Plans

Two Chinese companies, drug maker LianBio and hotel operator Atour, are moving ahead with U.S. IPOs after a three-month pause on such listings.

LIAN Financial details

Company Rating

Neutral

Market Cap

160.75M

Income

-85.84M

Revenue

Book val./share

2.07

Cash/share

2.49

Dividend

Dividend %

Employees

163

Optionable

Shortable

Yes

Earnings

10 Nov 2023

P/E

-1.86

Forward P/E

PEG

0.22

P/S

P/B

0.72

P/C

0.6

P/FCF

-1.88

Quick Ratio

12.4

Current Ratio

12.62

Debt / Equity

0.01

LT Debt / Equity

0.01

EPS (TTM)

-0.79

EPS next Y

EPS next Q

EPS this Y

-82.14%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-9.09%

SMA20

SMA50

SMA100

Inst Own

74.32%

Inst Trans

-0.69%

ROA

-31%

ROE

-35%

ROC

-0.41%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

107.17M

Shs Float

43.24M

Target Price

52W Range

1.07-2.9

52W High

-25.01%

52W Low

+49.99%

RSI

Rel Volume

0.2

Avg Volume

212.39K

Volume

42.5K

Perf Week

-0.01%

Perf Month

-18.92%

Perf Quarter

-25.01%

Perf Half Y

-9.1%

Beta

Volatility

0.01%, 0.14%

Prev Close

0.66%

Price

1.4999

Change

-0.54%

LIAN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0
Net income per share	0	-1.33	-5.71	-1.02
Operating cash flow per share	0	-0.93	-4.77	-0.92
Free cash flow per share	0	-0.94	-4.79	-0.94
Cash per share	0	2.42	11.14	2.8
Book value per share	0	-1.26	10.28	2.41
Tangible book value per share	0	-0.93	11.26	2.72
Share holders equity per share	0	-1.26	10.28	2.41
Interest debt per share	0	0.02	0.15	-0.1
Market cap	0	1.44B	211.87M	176.99M
Enterprise value	-42.77M	1.19B	-11.48M	102.11M
P/E ratio	0	-10.33	-1.08	-1.6
Price to sales ratio	0	0	0	0
POCF ratio	0	-14.69	-1.29	-1.78
PFCF ratio	0	-14.56	-1.28	-1.75
P/B Ratio	0	-10.86	0.6	0.68
PTB ratio	0	-10.86	0.6	0.68
EV to sales	0	0	0	0
Enterprise value over EBITDA	0	-8.83	0.06	-0.81
EV to operating cash flow	0	-12.12	0.07	-1.03
EV to free cash flow	0	-12.01	0.07	-1.01
Earnings yield	0	-0.1	-0.93	-0.62
Free cash flow yield	0	-0.07	-0.78	-0.57
Debt to equity	-0.03	-0.01	0.01	0.02
Debt to assets	0.01	0.01	0.01	0.01
Net debt to EBITDA	0	1.87	1.14	0.6
Current ratio	12.96	44.45	26.48	13.24
Interest coverage	0	0	-804.81	8.51
Income quality	0	0.7	0.84	0.9
Dividend Yield	0	0	0	0
Payout ratio	0	0	0	0
Sales general and administrative to revenue	0	0	0	0
Research and developement to revenue	0	0	0	0
Intangibles to total assets	0	0	0	0
Capex to operating cash flow	0	0.01	0.01	0.02
Capex to revenue	0	0	0	0
Capex to depreciation	0	-11.66	-1.8	-1.83
Stock based compensation to revenue	0	0	0	0
Graham number	0	6.14	36.33	7.44
ROIC	0	1.04	-0.54	-0.47
Return on tangible assets	0	-0.5	-0.46	-0.34
Graham Net	0	-1.02	10.05	2.57
Working capital	40M	270.52M	384.56M	289.16M
Tangible asset value	-14.82M	-98.07M	387.34M	293.65M
Net current asset value	-15.35M	-100.61M	360.64M	286.46M
Invested capital	-0.03	-0.01	0.01	0.02
Average receivables	0	10.13M	13.15M	3.91M
Average payables	0	2.16M	3.78M	2.34M
Average inventory	0	0	-3.02M	-3.02M
Days sales outstanding	0	0	0	0
Days payables outstanding	0	0	0	0
Days of inventory on hand	0	0	0	0
Receivables turnover	0	0	0	0
Payables turnover	0	0	0	0
Inventory turnover	0	0	0	0
ROE	0	1.05	-0.56	-0.42
Capex per share	0	-0.01	-0.03	-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	0	0	0	0	0
Net income per share	-0.39	-0.2	-0.17	-0.22	-0.2
Operating cash flow per share	-0.37	-0.15	-0.28	-0.16	-0.18
Free cash flow per share	-0.37	-0.16	-0.29	-0.16	-0.18
Cash per share	3.05	2.88	2.8	2.67	2.49
Book value per share	2.71	2.52	2.4	2.25	2.07
Tangible book value per share	3.02	2.83	2.72	2.56	2.38
Share holders equity per share	2.71	2.52	2.4	2.25	2.07
Interest debt per share	0.06	0.06	-0.07	0.01	0.03
Market cap	233.11M	216.71M	177.33M	210.04M	244.33M
Enterprise value	104.24M	142.61M	102.45M	111.62M	143.58M
P/E ratio	-1.37	-2.47	-2.43	-2.18	-2.83
Price to sales ratio	0	0	0	0	0
POCF ratio	-5.92	-13.57	-5.77	-11.91	-12.65
PFCF ratio	-5.87	-12.82	-5.73	-11.9	-12.62
P/B Ratio	0.8	0.79	0.68	0.87	1.1
PTB ratio	0.8	0.79	0.68	0.87	1.1
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-2.42	-5.88	-3.5	-4.35	-5.73
EV to operating cash flow	-2.65	-8.93	-3.34	-6.33	-7.43
EV to free cash flow	-2.62	-8.44	-3.31	-6.32	-7.41
Earnings yield	-0.18	-0.1	-0.1	-0.11	-0.09
Free cash flow yield	-0.17	-0.08	-0.17	-0.08	-0.08
Debt to equity	0.02	0.02	0.02	0.02	0.01
Debt to assets	0.01	0.01	0.01	0.01	0.01
Net debt to EBITDA	3	3.05	2.56	3.84	4.02
Current ratio	15.8	14.72	13.24	11.42	12.62
Interest coverage	-78.01	-17.47	2.42	10.99	0
Income quality	0.93	0.73	1.68	0.73	0.89
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.06	0.01	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-2.38	-3.35	-0.74	-0.06	-0.15
Stock based compensation to revenue	0	0	0	0	0
Graham number	4.89	3.38	3.02	3.37	3.06
ROIC	-0.14	-0.09	-0.11	-0.11	-0.11
Return on tangible assets	-0.11	-0.06	-0.06	-0.08	-0.08
Graham Net	2.69	2.53	2.57	2.42	2.28
Working capital	321.96M	302.21M	289.16M	270.13M	251.46M
Tangible asset value	326.2M	306.6M	293.65M	274.43M	255.51M
Net current asset value	298.09M	278.99M	286.46M	267.89M	249.81M
Invested capital	0.02	0.02	0.02	0.02	0.01
Average receivables	9.04M	9.18M	5.63M	2.86M	2.49M
Average payables	4.58M	1.63M	1.74M	3.44M	3.67M
Average inventory	0	0	0	-1.98M	-1.98M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.14	-0.08	-0.07	-0.1	-0.1
Capex per share	0	-0.01	0	0	0

LIAN Frequently Asked Questions

What is LianBio stock symbol ?

LianBio is a US stock , located in Princeton of Nj and trading under the symbol LIAN

What is LianBio stock quote today ?

LianBio stock price is $1.4999 today.

Is LianBio stock public?

Yes, LianBio is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 212.39K
Market Capitalization 160.75M
Employee 163
CEO Dr. Yizhe Wang Ph.D.
Headquarters Princeton,NJ,US
IPO Date 2021-11-01
Website https://www.lianbio.com

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.